Health ยท DR Congo
Ebola Vaccine Trials in DR Congo Could Yield Results Early Next Year if Insecurity Is Overcome
The head of the Coalition for Epidemic Preparedness Innovations says trials of three vaccines against Bundibugyo Ebola in DR Congo could produce results early next year in the best case, but conflict, misinformation and slow enrolment of participants remain major risks.
Large-scale trials of three vaccines against the Bundibugyo strain of Ebola in DR Congo could deliver results early next year in the best case, but insecurity in the east of the country threatens to slow progress, according to officials from two global vaccine bodies.
Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI), said a result could come in early next year at best. He noted that Congolese and global regulators would still need time to review any data before a formal decision on emergency authorisation. He added that expanded access might be possible during that review if regulators approve. Emanuele Capobianco, director of global health security at GAVI, said successful trials could allow vaccines to be deployed in the first half of 2027.
The Tumaini trial will test candidate vaccines on at least 1,000 people for safety and efficacy. A trial of Ervebo, a Merck vaccine approved against the Zaire strain of Ebola, began on 23 October in Ituri, the worst-affected province. Two vaccines designed for the Bundibugyo strain, one developed by Oxford University scientists and one by Moderna, are due to join in the next few days. Hatchett said testing could be extended to other provinces, including North Kivu.
The outbreak, declared in May, has killed more than 5,500 people and caused more than 11,000 cases, making it the second-largest Ebola outbreak recorded. No vaccine has been proven against this strain. Most cases are in the conflict-affected east, where the army has long fought rebel groups including M23. DR Congo's government accuses Rwanda of backing M23, which Kigali denies. Health workers and surveillance teams have been attacked in communities that distrust outsiders.
Hatchett said the main uncertainty was how quickly enough participants could be enrolled, citing conflict and misinformation. Capobianco said the involvement of health workers, religious leaders and community authorities would be crucial.
The World Health Organization said this week that 400 to 500 new cases are still being reported weekly. It added that delays in paying frontline workers have created tension and slowed the response.